Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2018 08:30 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® to Present at the 2018 Bank of America Merrill Lynch Health Care Conference

BOTHELL, Wash., May 07, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
April 30, 2018 08:30 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2018 Financial and Operating Results

BOTHELL, Wash., April 30, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
April 26, 2018 08:30 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Appoints Jeremy Green to its Board of Directors

BOTHELL, Wash., April 26, 2018 (GLOBE NEWSWIRE) -- Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) (“Alder” or the “Company”), a biopharmaceutical company focused on developing novel therapeutic...
April 25, 2018 08:30 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to 32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine

BOTHELL, Wash., April 25, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
April 24, 2018 08:30 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine

- Data presented at AAN Annual Meeting demonstrate eptinezumab further reduces migraine risk following the third and fourth quarterly infusions - More than 50% of patients achieved a 75% reduction or...
April 23, 2018 08:30 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Appoints Eric Carter, Ph.D., M.D., as Interim Chief Medical Officer

BOTHELL, Wash., April 23, 2018 (GLOBE NEWSWIRE) -- Alder Biopharmaceuticals, Inc., (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
April 18, 2018 08:30 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® to Present New Phase 3 Migraine Prevention Data for Eptinezumab at the 70th Annual American Academy of Neurology Meeting

BOTHELL, Wash., April 18, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
April 16, 2018 08:30 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Appoints Erin Lavelle to Newly Created Role of Chief Operating Officer

BOTHELL, Wash., April 16, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) (“Alder” or the “Company”), a biopharmaceutical company focused on developing novel therapeutic...
March 20, 2018 16:05 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Appoints Paul B. Cleveland as Interim President and Chief Executive Officer

BOTHELL, Wash., March 20, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
March 05, 2018 16:05 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® to Present at 38th Annual Cowen & Co. Health Care Conference

BOTHELL, Wash., March 05, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right